People In Business NASDAQ 1

USA

Sangeeta N. Bhatia starts fourth year as Vertex Pharmaceuticals Independent Director 18 June 2018

NEWS BITES - PEOPLE IN BUSINESS

Sangeeta N. Bhatia was appointed Independent Director of Vertex Pharmaceuticals (NASDAQ:VRTX) three years ago on June 18, 2015. The shares were up from US$127.3 to US$155.0 and the total annualized return to shareholders (TRS) since appointment is 6.8%. The present value of USD1,000 (PV1000) invested on the appointment date is now worth US$1,217, a gain of US$217.

SECTION 1 BIOGRAPHY SANGEETA N. BHATIA, INDEPENDENT DIRECTOR

Dr. Bhatia joined the Vertex Board in June 2015. She currently serves as the John J. and Dorothy Wilson Professor of Health Sciences at the Massachusetts Institute of Technology's (MIT) Institute for Medical Engineering and Science and Electrical Engineering and ComputerScience (EECS), where she has worked since 2005.

SECTION 2 VERTEX PHARMACEUTICALS INCORPORATED PRICE PERFORMANCE SCORECARD (NASDAQ:VRTX):

2.1 Vertex Pharmaceuticals Incorporated is placed 793/2,194 in the BSS News Bites ranking of price performance of NASDAQ stocks in the past year, a percentile ranking of 63.

+ Sangeeta N. Bhatia became Independent Director of Vertex Pharmaceuticals Incorporated on Jun 18,2015. The company's performance, measured in average annualised shareholder returns in the past three years, has been below average in that time - investors have reaped 6% compared to 17% for the NASDAQ-100 Index.

2.2 MCap History:

Market Capitalization has increased by $US7.6 billion from $US31 billion to $US38.6 billion since appointment.

VRTXShare Price (USD)Market Capitalisation (USD)
Last152.1138.6 billion
1 Year ago123.1430.5 billion
2 Years ago90.8422.4 billion
Jun 18, 2015127.3431 billion

2.3 Moving Annual Return (Trailing 12 months):

Based on a dynamic start date of 4 years ago, the Moving Annual Return has been positive in 3 of the last 4 years. An investment in VRTX a year ago would have produced a return of 23.5%

VRTXCloseAnnual Return %
Last Traded Jun 18$US152.1123.5
1 Year ago$US123.1435.6
2 Years ago$US90.84-26.4
3 Years ago$US123.4969.5

Close 4 years ago $US72.88.

2.4 Present Value of $US1000 invested in the past

The present value of $US1000 invested a year ago is $US1,250

PV$10001-week1-month1-year
VRTX.NASDAQ1,0309971,250
NASDAQ-100 Index1,0151,0441,273

2.5 Trailing Price Change %

1-Year price change for Vertex Pharmaceuticals was 23.5%. Compared with the NASDAQ-100 Index which rose 27.0% in the year, the relative price change was -3.5%.

Price Change %1-Month3-Month1-Year
VRTX-2.6-13.423.5
Medical/Biomedical sector3.9-3.44.8
NASDAQ-100 Index5.12.827.0

SECTION 3 VERTEX PHARMACEUTICALS INCORPORATED FINANCIALS AND GROWTH PERFORMANCE SCORECARD (NASDAQ:VRTX):

3.1 Key Financials (All figures percent)

Operating Margin has improved from -54.0% in 2015 to -0.6% in 2017.

VRTXRevenue GrowthOperating MarginROE
201746.2-0.613
201664.9-4-9.7
201567.9-54-

3.2 Revenue and Net Profit

In the last 5 years Compound Annual Growth Rate (CAGR) averaged 10.3% for Total Revenue.

DescriptionAnnual ($US B)5-year Avg ($US B)5-year CAGR %
Total Revenue2.51.410.3

CAGR = Compound Annual Growth Rate

3.3 Performance (All figures in %)

Net Profit Margin 5-year average is -44.4% and Return on Equity 5-year average is -31.5%.

DescriptionAnnual5-year Avg
EBITDA Margin-0.6-41.5
Operating Profit Margin-0.6-44.5
Net Profit Margin3.7-44.4
Return on Equity13.0-31.5
Return on Assets2.6-14.9
Return on Capital Employed-0.6-19.4

3.4 High Performance Indicators:

DescriptionValueRank In NASDAQ Market
Turnover in Quarter$US14.4 billionIn Top 3%
Volatility %1.4In Top Quartile

SECTION 4 VERTEX PHARMACEUTICALS INCORPORATED GLOBAL RANK (NASDAQ:VRTX):

4.1 Global Rank

Rank in the NASDAQ-100 Index [out of 103 stocks]

DescriptionValueRank
MCap (US$)39.4B49
Total Assets (US$)3.5B94
Revenue (US$)2.4B85
Net Profit (US$)226M84
Return on Equity %13.065
Net Profit Margin %3.785
Price to Book20.246
PV$1000 (1Year) US$1,25044
% Change YTD2.966

SECTION 5 OTHER DIRECTORS OF VERTEX PHARMACEUTICALS INCORPORATED

Jeffrey Leiden, Chief Executive Officer & President & Chairman & Director

Ian Smith, Chief Financial Officer & Executive Vice President

Bruce I. Sachs, Director

David Altshuler, Director

Joshua Boger, Director

Elaine S. Ullian, Director

Terrence C. Kearney, Director

Margaret McGlynn, Director

Sangeeta N. Bhatia, Independent Director

Alan Garber, Independent Director

Yuchun Lee, Independent Director

Stuart A. Arbuckle, Executive Vice President

Michael J. Parin, Executive Vice President

Kimberly A. White, Senior Vice President

Amit K. Sachdev, Senior Vice President

Tom Graney, Senior Vice President

SECTION 6 VERTEX PHARMACEUTICALS INCORPORATED ACTIVITIES

Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company's principal drug candidate, is an oral hepatitis C protease inhibitor and an antiviral treatment in clinical development that targets hepatitis C virus (HCV) infection. As of December 31, 2008, Vertex was also developing, among other compounds, VX-770, a drug candidate for the treatment of patients with cystic fibrosis (CF). In March 2009, the Company completed its acquisition of ViroChem Pharma Inc., a company with two investigational HCV polymerase inhibitors in clinical development.

SECTION 7 RECENT NEWS ON DIRECTORS

7.1 REPORTED STOCK AWARDS

06 June 2018

Vertex Pharmaceuticals director Margaret McGlynn awarded shares

Vertex Pharmaceuticals (NASDAQ:VRTX) director Margaret McGlynn, was awarded 1,801 shares worth $US273,842 on June 01.

06 June 2018

Vertex Pharmaceuticals director Bruce I. Sachs awarded Stock Options

Vertex Pharmaceuticals (NASDAQ:VRTX) director Bruce I. Sachs, has been awarded Stock Options on 3,229 shares at an exercise price of $US152.74. The transaction date was June 01. The shares last traded at $US145.72, hitting an eight-month low on the day.

06 June 2018

Vertex Pharmaceuticals director Margaret McGlynn awarded Stock Options

Vertex Pharmaceuticals (NASDAQ:VRTX) director Margaret McGlynn, has been awarded Stock Options on 3,229 shares at an exercise price of $US152.74. The transaction date was June 01. The shares last traded at $US145.72, hitting an eight-month low on the day.

06 June 2018

Vertex Pharmaceuticals director Bruce I. Sachs awarded shares

Vertex Pharmaceuticals (NASDAQ:VRTX) director Bruce I. Sachs, was awarded 1,801 shares worth $US273,842 on June 01.

06 June 2018

Vertex Pharmaceuticals director Terrence C. Kearney awarded shares

Vertex Pharmaceuticals (NASDAQ:VRTX) director Terrence C. Kearney, was awarded 1,801 shares worth $US273,842 on June 01.

06 June 2018

Vertex Pharmaceuticals director Terrence C. Kearney awarded Stock Options

Vertex Pharmaceuticals (NASDAQ:VRTX) director Terrence C. Kearney, has been awarded Stock Options on 3,229 shares at an exercise price of $US152.74. The transaction date was June 01. The shares last traded at $US145.72, hitting an eight-month low on the day.

06 June 2018

Vertex Pharmaceuticals director Elaine S. Ullian awarded Stock Options

Vertex Pharmaceuticals (NASDAQ:VRTX) director Elaine S. Ullian, has been awarded Stock Options on 3,229 shares at an exercise price of $US152.74. The transaction date was June 01. The shares last traded at $US145.72, hitting an eight-month low on the day.

06 June 2018

Vertex Pharmaceuticals director Elaine S. Ullian awarded shares

Vertex Pharmaceuticals (NASDAQ:VRTX) director Elaine S. Ullian, was awarded 1,801 shares worth $US273,842 on June 01.

06 June 2018

Vertex Pharmaceuticals director Yuchun Lee awarded Stock Options

Vertex Pharmaceuticals (NASDAQ:VRTX) director Yuchun Lee, has been awarded Stock Options on 3,229 shares at an exercise price of $US152.74. The transaction date was June 01. The shares last traded at $US145.72, hitting an eight-month low on the day.

06 June 2018

Vertex Pharmaceuticals director Yuchun Lee awarded shares

Vertex Pharmaceuticals (NASDAQ:VRTX) director Yuchun Lee, was awarded 1,801 shares worth $US273,842 on June 01.

7.2 SHAREHOLDER VALUE ADDED BY DIRECTORS

04 January 2018

Michael J. Parin starts third year as Vertex Pharmaceuticals Executive Vice President

Michael J. Parin was appointed Executive Vice President of Vertex Pharmaceuticals (NASDAQ:VRTX) two years ago on January 04, 2016. The shares were up from $US122.9 to $US152.0 and the total annualized return to shareholders (TRS) since appointment is 11.2%. The present value of USD1,000 (PV1000) invested on the appointment date is now worth $US1,237, a gain of $US237.

7.3 RECENT REPORTED SELLING

05 June 2018

Vertex Pharmaceuticals director Sangeeta N. Bhatia sells

Vertex Pharmaceuticals (NASDAQ:VRTX) Independent Director Sangeeta N. Bhatia sold 875 shares worth $US133,044 on June 04. The selling price was $US152.05. The shares hit a one-month low on the day.

16 May 2018

Vertex Pharmaceuticals senior vice president Amit K. Sachdev sells

Vertex Pharmaceuticals (NASDAQ:VRTX) Senior Vice President Amit K. Sachdev sold 83 shares worth $US12,930 on May 15. The selling price was $US155.78.

16 May 2018

Vertex Pharmaceuticals executive vice president Stuart A. Arbuckle sells

Vertex Pharmaceuticals (NASDAQ:VRTX) Executive Vice President Stuart A. Arbuckle sold 138 shares worth $US21,498 on May 15. The selling price was $US155.78.

16 May 2018

Vertex Pharmaceuticals executive vice president Michael J. Parin sells

Vertex Pharmaceuticals (NASDAQ:VRTX) Executive Vice President Michael J. Parin sold 85 shares worth $US13,241 on May 15. The selling price was $US155.78.

Source: www.BuySellSignals.com